Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: guarantee (67), certify (28), warrant (16)

2025 WDES report and action plan

Description: Workforce Disability Equality Standard Annual Report 2025 1 Executive Summary The Workforce Disability Equality Standard (WDES) is a s
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/2025-wdes-report-and-action-plan.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Procedure for adult DXA

Description: NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance s
Url: /Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-adult-DXA.pdf

MP000 028 Cellular pathology user handbook v24

Description: University Hospital Southampton NHS Foundation Trust PATHOLOGY DIRECTORATE Cellular Pathology (Management) MP 000 028 Revision 24 Pa
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Cell-path/MP000-028-Cellular-pathology-user-handbook-v24.pdf

Bendamustine-Rituximab

Description: Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-RITUXIMAB There are multiple versions of this protocol in use. Please ensure you have the correct protocol
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Rituximab.pdf

MyelomaVTDBortezomib(SC)DexamethasoneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD (SC-28)-BORTEZOMIB (SC)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (28)-Bortezomib (SC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibSCDexamethasoneThalidomideVer1.pdf

MyelomaVTDBortezomib(IV)DexamethasoneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD (IV-28)-BORTEZOMIB (IV)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (IV-28)-Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibIVDexamethasoneThalidomideVer1.pdf

MyelomaMPTMelphalan(PO)PrednisoloneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPT-MELPHALAN (PO)-PREDNISOLONE-THALIDOMIDE Regimen Multiple Myeloma – MPT-Melphalan (PO)-Prednisolone-Thalidomid
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPTMelphalanPOPrednisoloneThalidomideVer1.pdf

Bendamustine_90_RituximabSplit

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA BENDAMUSTINE (90)-RITUXIMAB (Split) There are multiple versions of this protoc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-RituximabSplit.pdf

Bendamustine_90_Rituximab

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA BENDAMUSTINE (90)-RITUXIMAB There are multiple versions of this protocol in use that
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-Rituximab.pdf

141 to 150 of 1000

Previous … 13 14 15 16 17 … Next